112 related articles for article (PubMed ID: 31006216)
1. [Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis].
Liu YM; Lian F; Zhou XF; Chen WC; Liu HK; Yao W; Fan WZ; Li JP; Chen J; Wang Y
Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(15):1142-1146. PubMed ID: 31006216
[No Abstract] [Full Text] [Related]
2. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
Liu Y; Liu H; Chen W; Yu H; Yao W; Fan W; Li J; Chen M; Chen J; Wang Y
Cancer Med; 2022 Jul; 11(13):2588-2600. PubMed ID: 35289113
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization.
Liu Y; Chen W; Cui W; Liu H; Zhou X; Chen L; Li J; Chen M; Chen J; Wang Y
Neuroendocrinology; 2020; 110(7-8):697-704. PubMed ID: 31639795
[TBL] [Abstract][Full Text] [Related]
5. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
7. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts.
Tong H; Li X; Zhang CL; Gao JH; Wen SL; Huang ZY; Wen FQ; Fu P; Tang CW
J Dig Dis; 2013 Jan; 14(1):29-37. PubMed ID: 23134145
[TBL] [Abstract][Full Text] [Related]
9. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.
Pericleous M; Caplin ME; Tsochatzis E; Yu D; Morgan-Rowe L; Toumpanakis C
Asia Pac J Clin Oncol; 2016 Mar; 12(1):61-9. PubMed ID: 26663886
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
11. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Rinke A; Wittenberg M; Schade-Brittinger C; Aminossadati B; Ronicke E; Gress TM; Müller HH; Arnold R;
Neuroendocrinology; 2017; 104(1):26-32. PubMed ID: 26731483
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy, prognosis and influencing factors of transcatheter arterial embolization in the treatment of neuroendocrine neoplasm liver metastases].
Zhang Y; Xu RT; Bai JA; Hu P; Li XY; Tian Y; Tang QY
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2952-2958. PubMed ID: 37752055
[No Abstract] [Full Text] [Related]
13. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
14. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L; Vinik AI
Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
[TBL] [Abstract][Full Text] [Related]
17. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract][Full Text] [Related]
18. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
Shen C; Xu Y; Dasari A; Shih YC; Yao JC
Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
[TBL] [Abstract][Full Text] [Related]
19. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
